Schedule of Accreditation

issued by

United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK



7204

Accredited to ISO/IEC 17043:2023

Sheffield Teaching Hospitals NHS Foundation Trust, operating UK NEQAS for Leucocyte Immunophenotyping

Issue No: 012 Issue date: 25 June 2025

4th Floor Pegasus House 463a Glossop Road

Sheffield S10 2QD

United Kingdom

Contact: Joanne Antcliff Tel: +44 (0)1142 673 600 Fax: +44 (0)1142 673 601

E-Mail: joanne.antcliff@ukneqasli.co.uk

Website: www.uknegasli.co.uk

Proficiency Testing provided from the locations specified below

Locations covered by the organisation and their relevant activities

Location details		Activity	Location code
Address 4th Floor Pegasus House 463a Glossop Road Sheffield S10 2QD United Kingdom	Local Contact Joanne Antcliff Tel: +44 (0)1142 673 600 Fax: +44 (0)1142 673 601	PT offices and main operations	A
Address Dept of Haematology-H Floor, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Glossop Rd, Sheffield, South Yorkshire S10 2JF	Local Contact As above	Sample preparation, including in process testing.	В
Academic Unit of Molecular Oncology within the Dept of Oncology and Metabolism, G Floor, Royal Hallamshire Hospital (University of Sheffield facilities)	Local Contact As above	Gamma irradiation of flow cytometric samples	С
Department of Infection, Immunity and Cardiovascular Disease – K Floor, Royal Hallamshire Hospital (University of Sheffield facilities)	Local Contact As above	Sample preparation	D

Assessment Manager: DE Page 1 of 4



Accredited to ISO/IEC 17043:2023

Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Sheffield Teaching Hospitals NHS Foundation Trust, operating UK NEQAS for Leucocyte Immunophenotyping

Issue No: 012 Issue date: 25 June 2025

Proficiency Tests provided from the locations specified

DETAIL OF ACCREDITATION

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used	Location Code
	Flow Cytometry Programmes	See www.ukneqasli.co.uk for scheme details	
Stabilised whole human blood	Immune monitoring (Absolute and percentage lymphocyte subsets)		A, B, C
Stabilised whole human blood	CD34+ Stem Cell Enumeration (Absolute CD34+ stem cell numbers subsets)		A, B, C
Stabilised whole human blood	Leukaemia Immunophenotyping and diagnostic interpretation (Surface antigen expression and case diagnosis)		A, B, C
Stabilised whole human blood	Low level leucocyte enumeration (Absolute leucocyte count)		A, B, C
Stabilised human blood	Measurable residual Disease for ALL by Flow Cytometry		A, B, C
	(Percentage MRD population as a function of total leucocytes)		A, B, C
Stabilised whole human blood	Paroxysmal Nocturnal Haemoglobinuria (Size of PHN population, Clone presence /absence)		A, B, C
	Molecular Haemato- oncology		
Lyophilised cells	JAK2 p.Val617Phe (V617F) Mutation status (Presence of JAK2 V617F mutation)		A, D
Blood or Lyophilised cells	IG/TCR Clonality Status (Identification of IG/TCR clones)		A, D

Assessment Manager: DE Page 2 of 4



Accredited to ISO/IEC 17043:2023

Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Sheffield Teaching Hospitals NHS Foundation Trust, operating UK NEQAS for Leucocyte Immunophenotyping

Issue No: 012 Issue date: 25 June 2025

Proficiency Tests provided from the locations specified

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/	Location Code
	resur roperties inteasured	Techniques Used	Code
	Molecular Haemato- oncology (cont'd:)	See www.ukneqasli.co.uk for scheme details	
Blood or Lyophilised cells	Post-SCT Chimerism Monitoring		A, D
Lyophilised cells	BCR::ABL1 Major Quantification (Level of BCR::ABL mutation)		A, D
Lyophilised cells	BCR::ABL1 Minor Quantification (Level of BCR::ABL1 mutation)		A, D
Lyophilised cells	BCR::ABL1 and AML translocation Identification (Presence of BCR::ABL1 and other translocations) t(15;17) PML::RARA inv16 CBFB::MYH11 t(8;21) RUNX1::RUNX1T1 t(9:22) BCR::ABL1 (e1a2, e13a2, e14a2)		A, D
Lyophilised cells	BCR::ABL1 Kinase Domain Variant (Mutation) Status		A, D
Lyophilised cell line samples	BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia		A, D
Lyophilised cell line samples	KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease		A, D
Blood or Lyophilised cells	NPM1 Mutation Status (Presence of NPM1 mutation)		A, D
Blood or Lyophilised cells	FLT3 Mutation Status (Presence of FLT3 mutation)		A, D
Blood or Lyophilised cells	Paediatric Acute Leukaemia Translocations (1. t(1;19) (TCF3::PBX1) 2. t(12;21) (ETV6::RUNX1) 3. t(4;11) (KMT2a::AFF1)		A, D

Assessment Manager: DE Page 3 of 4



Accredited to ISO/IEC 17043:2023

Schedule of Accreditation issued by

United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Sheffield Teaching Hospitals NHS Foundation Trust, operating UK NEQAS for Leucocyte Immunophenotyping

Issue No: 012 Issue date: 25 June 2025

Proficiency Tests provided from the locations specified

Materials/Products	Scheme Name/Type of Test/Properties Measured	Scheme Protocols/Procedures/ Techniques Used	Location Code	
	Molecular Haemato- oncology (cont'd:)	See www.ukneqasli.co.uk for scheme details		
Lyophilsed cell line samples	Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia (<i>MYD88</i> p.Leu265Pro (L265P) variant)		A D	
END				

Assessment Manager: DE Page 4 of 4